BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)
BTIG analyst Justin Zelin maintained a Buy rating for Ascentage Pharma Group International Unsponsored ADR, setting a price target of $50.00. Zelin, a 4-star analyst with an 8.0% average return, focuses on the Healthcare sector. The analyst consensus for Ascentage Pharma is Strong Buy, with a price target consensus of $49.67.
Tip Ranks·